Phase 1 N=138 A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=103 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
Chronic Hepatitis C Virus
Primary: Percentage of Participants Experiencing Treatment Emergent Adverse Events — 17.6; 25.0; 26.7; 8.3 percentage of participants
Phase 1 N=24 A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Required Adverse Events Grade II, III, and IV, Laboratory Adverse Events Grade II, III, and IV, and Severe Considered Adverse Events Related to…
Phase 1 N=312 To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) — 2656.5; 2469.7; 2690.6 h•μg/mL
Phase 1 N=20 Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment
Hepatitis B Virus
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAF — 120.6; 228.2; 219.9; 304.0 h*ng/mL
Phase 1 N=12 A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-906 — 14.37; 89.62 nanogram per milliliter (ng/mL)
Phase 1 N=53 Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
HIV-1 Infection
Primary: Part A and Part B: Maximum Reduction From Day 1 (Baseline) Through Day 10 in Plasma HIV-1 RNA — -1.35; -1.79; -1.76; -2.20 log10 copies/mL — p=<0.0001
Phase 1 N=57 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy
Healthy Participants · Narcolepsy
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 1; 0; 2; 4 Participants
Phase 1 N=17 tTF-NGR Phase I Study
Malignant Solid Tumors · Lymphomas
Primary: Maximum Tolerated Dose (MTD) and Dose-limiting Toxicity (DLT) — 8; 5; 4 Participants
Phase 1 N=190 A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.
Healthy Volunteers
Primary: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of SHP643 in Plasma — 348.9; 376.5 day*microgram per…
Phase 1 N=7 Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization
Antibiotic Resistant Strain
Primary: Number of Participants With Adverse Events (NIH Grade ≥2) at Day 7 After Randomization — 4; 0 Participants
Phase 1 N=180 To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17
Healthy
Primary: Peak Plasma Concentration (Cmax) — 4.141; 3.908 μg/mL
Phase 1 N=22 DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
Plasmodium Falciparum, Malaria
Primary: Infection Rate — 5; 6; 3; 0 Participants
Phase 1 N=4 Challenge Infection of Healthy Adult Volunteers With RSV A2
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
Phase 1 N=60 Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
Glaucoma
Primary: Incidence of Events as of Primary Safety Outcomes — 0; 2; 0; 0 Number of events